Jennifer Hibma

The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin

Jennifer Hibma, Arik A. Zur, Richard A. Castro et al. · Clinical Pharmacokinetics · 2015 · 57 citations · Full text

Pharmacological Study, Biochemistry, Medicine +5

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin

Luke Fostvedt, Jennifer Hibma, Joanna C. Masters et al. · Clinical Pharmacology & Therapeutics · 2019 · 32 citations · Full text

Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer

Joseph Chen, Ana Ruiz-Garcı́a, Leonard P. James et al. · Clinical Pharmacology & Therapeutics · 2021 · 25 citations · Full text

Cancer Management, Pathology, Support Benefit–risk Assessment +19

Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia

Jennifer Hibma, Beverly Knight · Clinical Pharmacokinetics · 2018 · 21 citations

Hematological Malignancy, Oncology, Pharmacokinetic Modeling +10

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

Ana Ruiz-Garcı́a, Weiwei Tan, Jerry Li et al. · Pharmaceutics · 2020 · 16 citations · Full text